Price Alert

CorMedix Inc. (CRMD)

NASDAQ: CRMD · Real-Time Price · USD

12.80

-0.90 (-6.57%)

At close: Sep 04, 2025, 3:59 PM

12.68

-0.94%

Pre-market: Sep 05, 2025, 06:06 AM EDT

-6.57% (1D)

Bid	12.5
Market Cap	955.51M
Revenue (ttm)	121.48M
Net Income (ttm)	51.16M
EPS (ttm)	0.78
PE Ratio (ttm)	16.41
Forward PE	6.82
Analyst	Buy

Ask	13.41
Volume	4,810,074
Avg. Volume (20D)	3,107,511
Open	13.71
Previous Close	13.70
Day's Range	12.76 - 13.93
52-Week Range	5.31 - 17.43
Beta	1.71

About CRMD

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol CRMD

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for CRMD stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Next Earnings Release

CorMedix Inc. is scheduled to release its earnings on Oct 29, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

2 months ago

-16.44%

CorMedix shares are trading lower after the compan... Unlock content with Pro Subscription

2 months ago

-0.07%

CorMedix shares are trading lower after the company announced an $85 million public offering.

News

2 days ago · zacks.com

Wall Street Analysts Think CorMedix (CRMD) Could Surge 32.04%: Read This Before Placing a Bet

The mean of analysts' price targets for CorMedix (CRMD) points to a 32% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts ...

3 days ago · zacks.com

Is DefenCath Sufficient to Support CorMedix's Long-Term Growth Path?

CRMD's DefenCath, its only revenue source, posts $78.8M in sales in H1 2025, with exclusivity through 2033 fueling growth potential.

1 week ago · seekingalpha.com

CorMedix: The Undervalued Breakthrough

CorMedix has achieved GAAP profitability after years of losses, with the market yet to fully price in this turnaround. Shares trade at a moderate 17x forward P/E, but with a projected 8x forward P/E, ...

2 weeks ago · zacks.com

Wall Street Analysts Believe CorMedix (CRMD) Could Rally 45.63%: Here's is How to Trade

The average of price targets set by Wall Street analysts indicates a potential upside of 45.6% in CorMedix (CRMD). While the effectiveness of this highly sought-after metric is questionable, the posit...

3 weeks ago · zacks.com

Why CorMedix (CRMD) Might be Well Poised for a Surge

CorMedix (CRMD) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

4 weeks ago · seekingalpha.com

CorMedix, Inc. (CRMD) Q2 2025 Earnings Call Transcript

CorMedix, Inc. (NASDAQ:CRMD ) Q2 2025 Earnings Conference Call August 7, 2025 8:30 AM ET Company Participants Joseph Todisco - CEO & Director Matthew T. David - Executive VP & CFO Conference Call Part...

4 weeks ago · wsj.com

CorMedix to Buy Melinta Therapeutics for $300 Million

The buyer said the deal adds six marketed infectious-disease products to its offerings.

4 weeks ago · zacks.com

CorMedix (CRMD) Surpasses Q2 Earnings and Revenue Estimates

CorMedix (CRMD) came out with quarterly earnings of $0.28 per share, beating the Zacks Consensus Estimate of $0.2 per share. This compares to a loss of $0.25 per share a year ago.

4 weeks ago · businesswire.com

Melinta Therapeutics Announces Strategic Acquisition by CorMedix, Underscoring Its Portfolio Value and Industry Leadership

PARSIPPANY, N.J.--(BUSINESS WIRE)--Melinta Therapeutics Announces Strategic Acquisition by CorMedix, Underscoring its Portfolio Value and Industry Leadership.

1 month ago · zacks.com

CorMedix (CRMD) Earnings Expected to Grow: What to Know Ahead of Q2 Release

CorMedix (CRMD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Load More News